Article

Prognostic Value and Clinical Relevance of the 6th Edition 2002 American Joint Committee on Cancer Staging System in Patients with Resectable Hepatocellular Carcinoma

National Yang Ming University, T’ai-pei, Taipei, Taiwan
Journal of the American College of Surgeons (Impact Factor: 4.45). 11/2006; 203(4):426-35. DOI: 10.1016/j.jamcollsurg.2006.06.030
Source: PubMed

ABSTRACT A simplified American Joint Committee on Cancer (AJCC) TNM staging system for hepatocellular carcinoma (HCC) (the 6th edition) was proposed in 2002. In this study, we validated the prognostic value of the staging system in a patient cohort undergoing hepatic resection with longterm followup.
From a prospective database, the study cohort consisted of 440 patients who underwent curative hepatic resection for HCC between July 1991 and January 1999. Median followup time was 66 months. Multivariate analysis was performed to identify the independent prognostic factors related to postoperative survival. Patients were staged according to both the 5th edition (TNM-5) and 6th edition (TNM-6) AJCC TNM staging criteria.
The independent prognostic factors included major vascular invasion, microvascular invasion, surgical margin < 1 cm, indocyanine green retention rate at 15 minutes > 10%, multiple tumors, tumor rupture, male, and serum aspartate aminotransferase > 90 U/L. The breakdown by TNM-5 staging: I, 27 (6.1%); II, 108 (24.5%); III, 218 (49.5%); and IVA, 87 (19.8%) and by TNM-6 staging: I, 120 (27.3%); II, 170 (38.6%); and III, 150 (34.1%). When stratified according to the TNM-5 system, difference in survival was notable between stages II and IIIA (p < 0.001), between stages IIIA and IVA (p < 0.001), but not between stages I and II (p > 0.05). When stratified according to the TNM-6 system, difference in survival was considerable between stages I and II (p < 0.01), stages II and III (p < 0.001), and stages I and III (p < 0.001).
Overall, the TNM-6 staging system appears to provide a reliable prognostic classification of HCC patients and is simpler to use than the TNM-5 staging system.

0 Followers
 · 
92 Views
  • Source
    • "All of this evidence, including our results, support TNM-7 is superior to TNM- 6. However, studies (Chun et al. 2011; Poon et al. 2003; Lei et al. 2006; Kee et al. 2007; Minagawa et al. 2007; Li et al. 2010; Cheng et al. 2011) reported that the prognostic power of TNM-7 was relatively low in advanced stages. Chun et al. (2011) demonstrated that although a significant difference between adjoining early stages was identified, there was no significant difference in survival between adjoining advanced stages of TNM-7 (Cstage IIIB; all P [ 0.05). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the accuracy of the 7th edition of the American Joint Committee on Cancer staging system (TNM-7) for patients undergoing hepatectomy for hepatocellular carcinoma (HCC) and to propose a modified TNM system for better prediction of survival. Clinico-pathological data for 1,313 patients who underwent hepatectomy as initial treatment for HCC between 2000 and 2008 were retrieved from a prospective database. Overall survival (OS) and disease-free survival (DFS) were analyzed to evaluate the predictive value. The 1-, 3-, 5-year OS and DFS of 1,313 patients were 79.2, 55.4, 45.5 %, and 52.6, 36.1, 31.8 %, respectively. Multivariate analysis revealed that major vascular invasion was the most important prognostic factor for both OS and DFS, along with tumour number and size. Patients with pT1 and pT2 disease had significantly better OS and DFS than those with pT3 disease (P < 0.001). There was no significant difference between pT3a and pT4 (P = 0.552) but patients with pT3b disease had a worse OS and DFS than those with pT4 disease (P = 0.006 and P < 0.001, respectively). A modified TNM system within the existing framework was proposed to combine the current pT3a and pT4 together as the new pT3 and to change pT3b to the new pT4. Analysis showed that this modified system had a better prognostic power than either TNM-6 or TNM-7. TNM-7 would seem to be inaccurate for staging advanced HCC. The modified system can improve both the prognostic accuracy and the hazard discrimination of disease to be consistent among subgroups of HCC.
    Journal of Cancer Research and Clinical Oncology 08/2013; DOI:10.1007/s00432-013-1497-y · 3.01 Impact Factor
  • Source
    Journal of Mathematical Analysis and Applications 04/1988; 131(1):106–112. DOI:10.1016/0022-247X(88)90193-X · 1.12 Impact Factor
Show more